Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

56.50 -0.30 (-0.53%)
Streaming Delayed Price Updated: 11:29 AM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?
Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran. 
Via InvestorPlace
Where CRISPR Therapeutics Stands With Analysts
CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Will a Recession Cause a Housing Crash in 2022?
For stock investors looking for real estate exposure, the market dislocation also provides many once-a-decade deals. 
Via InvestorPlace
7 Undervalued Biotech Stocks to Buy Before They Boom
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy. 
Via InvestorPlace
Small Cap Biotech Stocks Are Trending Well
Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx. 
Via Talk Markets
Analyst Ratings for CRISPR Therapeutics
CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating
Crispr Therapeutics sees its Relative Strength Rating enter the elite 90-plus level. 
Via Investor's Business Daily
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
The group has several commonalities, including strong ratings and promising charts. 
Via Investor's Business Daily
6 Cathie Wood Stocks to Buy on the Dip
As major holdings in her portfolios, these Cathie Wood stocks to buy on the dips are likely to significantly pop when the market recovers. 
Via InvestorPlace
Fed To Hike Interest Rates 100 Basis Points? What To Expect From Stocks
The CPI report came in at 9.1% well above analyst expectations. Now there is a strong possibility of a 100 basis point rate hike at the next FOMC meeting. 
Via Talk Markets
5 Best Stocks to Buy if You Have $100 to Spend
My son became an investor this year, taking a job that pays more than his single, frugal lifestyle consumes. He asked me what stocks he might buy with 
Via InvestorPlace
The 3 Leaders of the Gene Editing Revolution
There's a wide field of gene editing stocks, but if you're looking for the best opportunities, there are a few likely winners to watch. 
Via InvestorPlace
7 Moonshot Investments Upending a $10 Trillion Industry
Gene editing is expensive at an estimated $5 billion per drug, but it could change the world in the very near future. 
Via InvestorPlace
7 Best Biotech Stocks to Buy in July 2022
The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict. 
Via InvestorPlace
Biotechs Say ESG Is Core To Their Mission; Do Investors Believe Them?
The biotech industry is trying to catch the ESG investing bug. But that doesn't mean investors are giving it credit, executives say. 
Via Investor's Business Daily
Jim Cramer Says This Company Isn't Making Money
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he is hearing nothing but positives of late about Nokia Corp (NYSE: NOK) over the previous four weeks. "I think it’s right to buy," he added. 
Via Benzinga
Evercore ISI Group Downgrades CRISPR Therapeutics: Here's What You Need To Know
Evercore ISI Group downgraded its rating of CRISPR Therapeutics (NASDAQ:CRSP) to In-Line with a price target of $60.00, changing its price target from $66.00 to $60.00. Shares of CRISPR Therapeutics... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
Upgrades 
Via Benzinga
Why CRISPR Therapeutics Stock Is Falling
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading lower Wednesday after several analysts adjusted price targets on the stock following the company's Innovation Day. 
Via Benzinga
Chardan Capital Maintains Buy Rating for CRISPR Therapeutics: Here's What You Need To Know
Chardan Capital has decided to maintain its Buy rating of CRISPR Therapeutics (NASDAQ:CRSP) and lower its price target from $168.00 to $164.00. Shares of CRISPR Therapeutics are trading down 8.24% over... 
Via Benzinga
Bear Market Rally Lifts HealthCare Stocks Off Bottom
Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma. 
Via Talk Markets
CNBC's Final Trades: Ethereum, Charles Schwab, Clean Energy, Boeing And This Biotech Stock
On CNBC’s “Halftime Report Final Trades,” Kevin O'Leary, known as "Mr. 
Via Benzinga
Do Crispr And Vertex Have A 'Functional Cure' For Blood Diseases?
Crispr and Vertex tested their gene-edited drug in two blood diseases. 
Via Investor's Business Daily
93 Biggest Movers From Yesterday
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... 
Via Benzinga
Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive
CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic... 
Via Benzinga
70 Stocks Moving In Monday's Mid-Day Session
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric... 
Via Benzinga
How Global Blood Therapeutics Thinks It Can Take On Crispr's Gene Editing
The company is using a different approach to tackle the blood disease. 
Via Investor's Business Daily
7 No-Brainer Biotech Stocks to Add to Your Buy List
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. 
Via InvestorPlace
7 Oversold Stocks to Buy Right Now
Identifying oversold stocks gives investors the opportunity to buy shares that they perhaps already liked, only at a discounted price. 
Via InvestorPlace
IBD Tech Leader Vertex Snags Upgrade As Non-Cystic Fibrosis Drugs Crystallize
One analyst expects multiple new drug launches between 2024-26. 
Via Investor's Business Daily
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.